Related Experiment Video
Updated: Jan 22, 2026

Studying the Role of Alveolar Macrophages in Breast Cancer Metastasis
Published on: June 26, 2016
New emerging targets in cancer immunotherapy: the role of TIM3
Alex Friedlaender1, Alfredo Addeo1, Giuseppe Banna2
1Oncology, Hopitaux Universitaires de Geneve, Geneva, Switzerland.
Abstract:
Currently, the programmed death-1/programmed death ligand-1 and the cytotoxic T-lymphocyte-associated protein 4 are the two commonly targeted immune-checkpoint inhibition pathways. These drugs have significantly improved the prognosis of many cancer types. While immune-checkpoint inhibitors have revolutionised the treatment of many cancer types, the majority of patients still progress. Several treatment strategies have been pursued to improve current results. One approach is to combine two checkpoint inhibitors, currently with promising results in melanoma, renal cell carcinoma and a subset of non-small-cell lung cancer patients. The identification of new checkpoint targets could allow the field of immuno-oncology to evolve further. We will discuss one of the most promising immune-checkpoint targets currently under investigation, the T-cell immunoglobulin and mucin domain-3.
Insights
Immune-checkpoint inhibitors like PD-1/PD-L1 and CTLA-4 improve cancer treatment, but many patients still progress. Investigating new targets, such as T-cell immunoglobulin and mucin domain-3 (TIM-3), is crucial for advancing immuno-oncology.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Immune-checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 have transformed cancer therapy.
- Despite significant improvements, many cancer patients do not respond to current checkpoint inhibitors.
- Combination therapies show promise but require further investigation.
Purpose of the Study:
- To review the current landscape of immune-checkpoint inhibition in cancer therapy.
- To highlight the limitations of existing treatments and the need for novel targets.
- To discuss T-cell immunoglobulin and mucin domain-3 (TIM-3) as a promising next-generation immune-checkpoint target.
Main Methods:
- Review of current literature on immune-checkpoint inhibitors.
- Analysis of clinical trial outcomes for combination therapies.
- Exploration of emerging immune-checkpoint targets, focusing on TIM-3.
Main Results:
- Established checkpoint inhibitors (PD-1/PD-L1, CTLA-4) offer significant survival benefits for specific cancers.
- Combination strategies are demonstrating encouraging results in melanoma, renal cell carcinoma, and non-small-cell lung cancer.
- TIM-3 emerges as a key target with potential to overcome resistance and improve patient outcomes.
Conclusions:
- Further research into novel immune-checkpoint targets like TIM-3 is essential for advancing immuno-oncology.
- Overcoming resistance to current therapies through new targets could benefit a broader patient population.
- TIM-3 represents a promising avenue for developing next-generation cancer immunotherapies.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Emerging Adulthood
Introduction Cardiac Emergencies
Applications of GIS: Disaster Management and Emergency Response
The Role of Culture

